BACKGROUND Atrial Fibrillation (AF) is common in the elderly. A key component of AF management is Oral Anticoagulant Therapy (OAT), consisting of Vitamin K Antagonists (VKAs) or Direct Oral Anticoagulants (DOACs). The aim of the present study is to check, using STOPP (Screening Tool of Older Persons’ Prescriptions)/START (Screening Tool to Alert to Right Treatment) Criteria, if such drugs are potentially inappropriately prescribed/omitted in an elderly population with AF, and to determine their impact on mortality. METHODS This study included patients (n=427) with nonvalvular AF consecutively evaluated between 2013 and 2019 at the Geriatric Outpatient Service, University Hospital of Monserrato, Cagliari, Italy, and followed-up for 36 months. The OAT-group included 330 patients; the other 97 patients constituted the non-OAT-group. The sample was assessed for STOPP/START criteria. RESULTS We found no difference (p>0.1) in comorbidity burden, frailty, and cardio-cerebro-vascular disease prevalence in the two groups, who also did not present difference in 36-month mortality (p=0.97). OAT was overall appropriately taken, and 62.4% of OAT-group presented the START criterion to take antiplatelets but also the STOPP criterion not to take them, because of the simultaneous anticoagulant intake. In the non-OAT-group, 69.1% presented the START criterion to take anticoagulants, and 21.6% the START criterion to take antiplatelets. CONCLUSIONS Patients with AF are often prone to under- or over-prescription, particularly of antithrombotic drugs. The STOPP/START criteria are a valid tool to assess and correct wrong therapeutic choices. In frail and comorbid subjects, survival is not correlated with the assumption of OAT.

STOPP/START antiaggregation and anticoagulation alerts in atrial fibrillation

Francesco Salis
Primo
Writing – Original Draft Preparation
;
Antonella Mandas
Ultimo
Supervision
2023-01-01

Abstract

BACKGROUND Atrial Fibrillation (AF) is common in the elderly. A key component of AF management is Oral Anticoagulant Therapy (OAT), consisting of Vitamin K Antagonists (VKAs) or Direct Oral Anticoagulants (DOACs). The aim of the present study is to check, using STOPP (Screening Tool of Older Persons’ Prescriptions)/START (Screening Tool to Alert to Right Treatment) Criteria, if such drugs are potentially inappropriately prescribed/omitted in an elderly population with AF, and to determine their impact on mortality. METHODS This study included patients (n=427) with nonvalvular AF consecutively evaluated between 2013 and 2019 at the Geriatric Outpatient Service, University Hospital of Monserrato, Cagliari, Italy, and followed-up for 36 months. The OAT-group included 330 patients; the other 97 patients constituted the non-OAT-group. The sample was assessed for STOPP/START criteria. RESULTS We found no difference (p>0.1) in comorbidity burden, frailty, and cardio-cerebro-vascular disease prevalence in the two groups, who also did not present difference in 36-month mortality (p=0.97). OAT was overall appropriately taken, and 62.4% of OAT-group presented the START criterion to take antiplatelets but also the STOPP criterion not to take them, because of the simultaneous anticoagulant intake. In the non-OAT-group, 69.1% presented the START criterion to take anticoagulants, and 21.6% the START criterion to take antiplatelets. CONCLUSIONS Patients with AF are often prone to under- or over-prescription, particularly of antithrombotic drugs. The STOPP/START criteria are a valid tool to assess and correct wrong therapeutic choices. In frail and comorbid subjects, survival is not correlated with the assumption of OAT.
2023
Atrial fibrillation; Comorbidities; Comprehensive Geriatric Assessment (CGA); Potentially Inappropriate Medication (PIM); Potentially Prescribing Omission; Screening Tool to Alert to Right Treatment (START); Screening Tool of Older Persons’ Prescriptions (STOPP); STOPP/START criteria
File in questo prodotto:
File Dimensione Formato  
Mandas pprint pdf.pdf

Open Access dal 05/05/2024

Tipologia: versione post-print
Dimensione 690.27 kB
Formato Adobe PDF
690.27 kB Adobe PDF Visualizza/Apri
STOPP START Anti-aggregation and anticoagulation alerts in Atrial Fibrillation.pdf

Solo gestori archivio

Tipologia: versione editoriale
Dimensione 1.55 MB
Formato Adobe PDF
1.55 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/358319
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact